Specify a stock or a cryptocurrency in the search bar to get a summary
Savara Inc
SVRASavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania. Address: 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047
Analytics
WallStreet Target Price
10.79 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SVRA
Dividend Analytics SVRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SVRA
Stock Valuation SVRA
Financials SVRA
Results | 2019 | Dynamics |